Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 2
2011 3
2012 1
2013 4
2014 5
2015 1
2016 3
2017 1
2019 4
2020 1
2021 1
2024 2
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO Registry.
Armenia D, Spagnuolo V, Bellocchi MC, Galli L, Duca L, Marchegiani G, Clemente T, Carioti L, Lolatto R, Calza L, Celesia BM, Cascio A, Francisci D, Saracino A, Torti C, Zazzi M, Castagna A, Santoro MM; PRESTIGIO Study Group. Armenia D, et al. J Antimicrob Chemother. 2024 Sep 3;79(9):2354-2363. doi: 10.1093/jac/dkae236. J Antimicrob Chemother. 2024. PMID: 39004997
Polypharmacy, anticholinergic burden and drug-drug interaction assessment in people with four-class-resistant HIV: data from the PRESTIGIO registry.
Mazzitelli M, Pontillo D, Clemente T, Di Biagio A, Cenderello G, Rusconi S, Menzaghi B, Fornabaio C, Garlassi E, Zazzi M, Castagna A, Cattelan AM; PRESTIGIO Study Group. Mazzitelli M, et al. Among authors: garlassi e. J Antimicrob Chemother. 2024 Sep 3;79(9):2163-2169. doi: 10.1093/jac/dkae190. J Antimicrob Chemother. 2024. PMID: 39001781
Lipodystrophy and quality of life of HIV-infected persons.
Guaraldi G, Murri R, Orlando G, Squillace N, Stentarelli C, Zona S, Garlassi E, Martínez E. Guaraldi G, et al. Among authors: garlassi e. AIDS Rev. 2008 Jul-Sep;10(3):152-61. AIDS Rev. 2008. PMID: 18820717 Review.
Two-fold increased risk of cardiovascular events in people with MDR HIV: a matched cohort analysis with data from the PRESTIGIO registry.
Clemente T, Diotallevi S, Minisci D, Di Biagio A, Lolatto R, Attala L, Cenderello G, Siribelli A, Muccini C, Lo Caputo S, Tavio M, Papaioannu Borjesson R, Giacomelli A, Castagna A, Spagnuolo V; PRESTIGIO Study Group. Clemente T, et al. J Antimicrob Chemother. 2025 Mar 3;80(3):731-737. doi: 10.1093/jac/dkae465. J Antimicrob Chemother. 2025. PMID: 39727173
Secukinumab in an HIV-positive patient with psoriasis.
Di Lernia V, Casanova DM, Garlassi E. Di Lernia V, et al. Among authors: garlassi e. J Dtsch Dermatol Ges. 2019 Jun;17(6):646-648. doi: 10.1111/ddg.13851. Epub 2019 May 17. J Dtsch Dermatol Ges. 2019. PMID: 31099169 No abstract available.
Secukinumab bei einer HIV-positiven Patientin mit Psoriasis.
Di Lernia V, Casanova DM, Garlassi E. Di Lernia V, et al. Among authors: garlassi e. J Dtsch Dermatol Ges. 2019 Jun;17(6):646-648. doi: 10.1111/ddg.13851_g. J Dtsch Dermatol Ges. 2019. PMID: 31241850 No abstract available.
Hepatocellular carcinoma in HIV-infected patients: check early, treat hard.
Berretta M, Garlassi E, Cacopardo B, Cappellani A, Guaraldi G, Cocchi S, De Paoli P, Lleshi A, Izzi I, Torresin A, Di Gangi P, Pietrangelo A, Ferrari M, Bearz A, Berretta S, Nasti G, Di Benedetto F, Balestreri L, Tirelli U, Ventura P. Berretta M, et al. Among authors: garlassi e. Oncologist. 2011;16(9):1258-69. doi: 10.1634/theoncologist.2010-0400. Epub 2011 Aug 25. Oncologist. 2011. PMID: 21868692 Free PMC article.
29 results